

GLAXOSMITHKLINE PLC
Form 6-K
October 17, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 17 October 2018

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

a) Description of the financial instrument

| | | |
|------------------------------|--|-----------|
| b) Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | |
| | Price(s) | Volume(s) |
| | £14.516 | 208 |
| | £14.516 | 226 |
| c) Price(s) and volume(s) | £14.516 | 792 |
| | £14.516 | 207 |
| | £14.516 | 226 |
| d) Aggregated information | Aggregated volume Price | |

1659

£14.516

- e) Date of the transaction 2018-10-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Vaccines
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - Ordinary shares of 25 pence each ('Ordinary Shares')
 - ISIN: GB0009252882

- a) Description of the financial instrument

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
- c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|----------|-----------|
| £14.516 | 141 |
| £14.516 | 117 |
| £14.516 | 167 |
| £14.516 | 117 |

d) Aggregated information
 Aggregated volume Price 543
 £14.516

e) Date of the transaction 2018-10-12

f) Place of the transaction London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S Dingemans

b) Position/status Chief Financial Officer

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

| Price(s) | Volume(s) |
|----------|-----------|
| £14.516 | 274 |
| £14.516 | 205 |

c) Price(s) and volume(s)

£14.516 560

£14.516 274

£14.516 205

d) Aggregated information
Aggregated volume Price

1518
£14.516

e) Date of the transaction

2018-10-12

f) Place of the transaction

London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr N Hirons
b) Position/status SVP, Global Ethics & Compliance

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

October 2018 on Ordinary
Shares held in the Company's
Deferred Annual Bonus Plan.

Price(s) Volume(s)
£14.516 101

£14.516 74

c) Price(s) and volume(s) £14.516 88

£14.516 101

£14.516 74

d) Aggregated information 438
Aggregated volume Price £14.516

e) Date of the transaction 2018-10-12
f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr B McNamara
 - b) Position/status CEO, GSK Consumer Healthcare
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053

b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.

| | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | \$38.47 | 84 |
| | \$38.47 | 82 |

| | |
|---------------------------|---------|
| d) Aggregated information | 166 |
| Aggregated volume | \$38.47 |

| | |
|-----------------------------|--------------------------------|
| e) Date of the transaction | 2018-10-12 |
| f) Place of the transaction | New York Stock Exchange (XNYS) |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|--------------------|-----------------------------------|
| a) Name | Mr L Miels |
| b) Position/status | President, Global Pharmaceuticals |

| | |
|------------------------------------|----------------------|
| c) Initial notification/ amendment | Initial notification |
|------------------------------------|----------------------|

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|--|
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 |
|--|--|

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

October 2018 on Ordinary
Shares held in the Company's
Deferred Annual Bonus Plan.

| Price(s) | Volume(s) |
|----------|-----------|
| £14.516 | 129 |

| | |
|---------|----|
| £14.516 | 93 |
|---------|----|

| | | |
|---------------------------|---------|-----|
| c) Price(s) and volume(s) | £14.516 | 162 |
|---------------------------|---------|-----|

| | |
|---------|----|
| £14.516 | 93 |
|---------|----|

| | |
|---------|-----|
| £14.516 | 129 |
|---------|-----|

| | |
|---------------------------|---------|
| d) Aggregated information | 606 |
| Aggregated volume Price | £14.516 |

| | |
|-----------------------------|---------------------------------|
| e) Date of the transaction | 2018-10-12 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|--------------------|---------------------------------------|
| a) Name | Ms K Terrell |
| b) Position/status | Chief Digital & Technology Officer |

| | |
|---------------------------------------|----------------------|
| c) Initial notification/ amendment | Initial notification |
|---------------------------------------|----------------------|

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|--|
| a) Description of the financial instrument | American Depositary Shares (‘ADSs’) ISIN: US37733W1053 |
|--|--|

| | | |
|------------------------------|--|-----------|
| b) Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 on ADSs held in the Company's Deferred Annual Bonus Plan. | |
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | \$38.47 | 28 |
| d) Aggregated information | n/a (single transaction) | |
| e) Date of the transaction | 2018-10-12 | |
| f) Place of the transaction | New York Stock Exchange (XNYS) | |

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms C Thomas
 - b) Position/status SVP, Human Resources
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

a) Description of the financial instrument

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

October 2018 on Ordinary
Shares held in the Company's
Deferred Annual Bonus Plan.

| Price(s) | Volume(s) |
|----------|-----------|
| £14.516 | 189 |

| | |
|---------|-----|
| £14.516 | 141 |
|---------|-----|

| | | |
|---------------------------|---------|-----|
| c) Price(s) and volume(s) | £14.516 | 177 |
|---------------------------|---------|-----|

| | |
|---------|-----|
| £14.516 | 189 |
|---------|-----|

| | |
|---------|-----|
| £14.516 | 141 |
|---------|-----|

| | |
|---------------------------|---------|
| d) Aggregated information | 837 |
| Aggregated volume Price | £14.516 |

| | |
|-----------------------------|---------------------------------|
| e) Date of the transaction | 2018-10-12 |
| f) Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr P C Thomson
 - b) Position/status President, Global Affairs
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

| | | |
|------------------------------|--|-----------|
| | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | |
| b) Nature of the transaction | Price(s) | Volume(s) |
| | £14.516 | 115 |
| c) Price(s) and volume(s) | £14.516 | 88 |
| | £14.516 | 110 |
| d) Aggregated information | 313 | |
| Aggregated volume | £14.516 | |
| e) Date of the transaction | 2018-10-12 | |
| f) Place of the transaction | London Stock Exchange (XLON) | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: October 17, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc